ALE1
Phase 2Small molecule
ALE1 is one of 6 small molecule programs targeting Hypophosphatasia. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Hypophosphatasia
#DrugCompanyPhaseTrials
1Rituxan
RocheApproved
Trexall
Jazz PharmaceuticalsApproved
Fosrenol
TakedaApproved
Velcade
SShilpa Grover, MD, MPH
Approved
ALXN1850
AstraZenecaPhase 3
ALE1
AAlesta Therapeutics
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hypophosphatasia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ALE1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAlesta Therapeutics